Transcription inhibition by flavopiridol: Mechanism of chronic lymphocytic leukemia cell death

Blood

Volumn 106, Issue 7, 2005, Pages 2513-2519

  Chen, Rong ^a   Keating, Michael J ^a   Gandhi, Varsha ^a   Plunkett, William ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; FLAVOPIRIDOL; FLUDARABINE; MESSENGER RNA; PROTEIN BCL 2; PROTEIN MCL 1; RNA POLYMERASE II;

ARTICLE; BONE MARROW CELL; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; PHOSPHORYLATION; PRIORITY JOURNAL; RNA SYNTHESIS; TRANSCRIPTION REGULATION;

EID: 27144434812     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-04-1678     Document Type: Article

References (59)

1. Kay NE, Hamblin TJ, Jelinek DF, et al. Chronic lymphocytic leukemia. Hematology. 2002;99:193-213.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.
3. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol. 1998;25:11-18.
4. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood. 1998;91:3379-3389.
5. Pepper C, Thomas A, Hoy T, Cotter F, Bentley P. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;107:611-615.
6. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002;100:194-199.
7. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAILinduced apoptosis. Cell Death Differ. 2004;11:915-923.
8. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
9. Schriever F, Huhn D. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia. Drugs. 2003;63:953-969.
10. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-3281.
11. Thornton PD, Gruszka-Westwood AM, Hamoudi RA, et al. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J. 2004;5:47-54.
12. Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol. 2001;38:139-170.
13. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 1998;92:3804-3816.
14. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxystaurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood. 2000;96:393-397.
15. Pepper C, Thomas A, Hoy T, Fegan C, Bentley P. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol. 2001;114:70-77.
16. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered as a pharmacologically derived schedule demonstrates marked clinical activity in refractory, genetically high risk, chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2004;104:101a. Abstract 341.
17. Chao SH, Fujinaga K, Marion JE, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem. 2000;275:28345-28348.
18. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem. 2001;276:31793-31799.
19. Lam L, Pickeral O, Peng A, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2001;2:research0041.0001-research0041.0011.
20. Carson BA, Pearlstein RA, Nail RG, Sedlacek HH, Sausville EA, Worland PJ. Inhibition of cdk2, cdk4 and cdk7 by Flavopiridol and structural analogs [abstract]. Proc Amer Assoc Cancer Res. 1996;37:424. Abstract 2897.
21. Palancade B, Bensaude O. Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation. Eur J Biochem. 2003;270:3859-3870.
22. Sims RJ 3rd, Belotserkovskaya R, Reinberg D. Elongation by RNA polymerase II: the short and long of it. Genes Dev. 2004;18:2437-2468.
23. Marshall NF, Peng J, Xie Z, Price DH. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J Biol Chem. 1996;271:27176-27183.
24. Reed JC, Tsujimoto Y, Alpers JD, Croce CM, Nowell PC. Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science. 1987;236:1295-1299.
25. Schiavone N, Rosini P, Quattrone A, et al. A conserved AU-rich element in the 3′ untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis. FASEB J. 2000;14:174-184.
26. Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant S. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia. 2004;18:1780-1788.
27. Rudek MA, Bauer KS Jr, Lush RM III, et al. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother. 2003;37:1369-1374.
28. Merino R, Ding L, Veis DJ, Korsmeyer SJ, Nunez G. Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J. 1994;13:683-691.
29. Blagosklonny MV, Alvarez M, Fojo A, Neckers LM. bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells. Leuk Res. 1996;20:101-107.
30. McNeish IA, Lopes R, Bell SJ, et al. Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp Cell Res. 2005;302:69-82.
31. Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res. 2004;10:4270S-4275S.
32. Napolitano G, Majello B, Lania L. Role of cyclinT/Cdk9 complex in basal and regulated transcription. Int J Oncol. 2002;21:171-177.
33. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115:755-764.
34. Lolli G, Lowe ED, Brown NR, Johnson LN. The crystal structure of human CDK7 and its protein recognition properties. Structure (Camb). 2004;12:2067-2079.
35. Fisher RP, Morgan DO. A novel cyclin associates with M015/CDK7 to form the CDK-activating kinase. Cell. 1994;78:713-724.
36. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res. 2002;8:3527-3538.
37. Hahntow IN, Schneller F, Oelsner M, et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia. 2004;18:747-755.
38. Alvi AJ, Austen B, Weston VJ, et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood. 2005;105:4484-4491.
39. Stellrecht CM, Rodriguez CO Jr, Ayres M, Gandhi V. RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res. 2003;63:7968-7974.
40. Balakrishnan K, Stellrecht CM, Genini D, et al. Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood. 2005;105:4455-4462.
41. Huang P, Sandoval A, Van Den Neste E, Keating MJ, Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia. 2000;14:1405-1413.
42. Chen CY, Shyu AB. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci. 1995;20:465-470.
43. Chen CY, Xu N, Shyu AB. mRNA decay mediated by two distinct AU-rich elements from c-fos and granulocyte-macrophage colony-stimulating factor transcripts: different deadenylation kinetics and uncoupling from translation. Mol Cell Biol. 1995;15:5777-5788.
44. Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science. 1986;234:364-368.
45. Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. Trends Biochem Sci. 1996;21:267-271.
46. Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol. 1995;128:1173-1184.
47. ARE database. http://rc.kfshrc.edu.sa/bssc/ARED_GENE/search.asp. Accessed on August 5, 2005.
48. Michels J, Johnson PW, Packham G. Mcl-1. Int J Biochem Cell Biol. 2005;37:267-271.
49. Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 2004;5:25-35.
50. Carter BZ, Milella M, Tsao T, et al. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia. 2003;17:2081-2089.
51. Herrant M, Jacquel A, Marchetti S, et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene. 2004;23:7863-7873.
52. Michels J, O'Neill JW, Dallman CL, et al. Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene. 2004;23:4818-4827.
53. Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science. 2002;297:63-64.
54. Workman P. Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction. Expert Rev Anticancer Ther. 2002;2:611-614.
55. Johnson AJ, Lucas DM, Smith LL, et al. Clinical rebirth of flavopiridol in chronic lymphocytic leukemia (CLL): utilizing in vitro and in vivo pharmacodynamic measurements to improve efficacy and interrogate relevant mechanism(s) of action [abstract 1672]. Proc Amer Assoc Cancer Res. 2005;46:374.
56. Senderowicz A, Headlee D, Stinson S, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin- dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998;16:2986-2999.
57. Thomas JP, Tutsch KD, Cleary JF, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol. 2002;50:465-472.
58. Grant S, Dent P. Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name? Mol Cancer Ther. 2004;3:873-875.
59. Tan AR, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol. 2002;20:4074-4082.